Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — H.C. Wainwright 27th Annual Global Investment Conference 2025
12 slides from Insight Molecular Diagnostics's conference presentation, September 2025
Slide 1: Investor Presentation
Investor Presentation NASDAQ:IMDX September 2025 iMDxinc.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements Safe-Harbor Statement This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on the Insight Molecular Diagnostics, Inc.’s (iMDx) management’s beliefs and assumptions and on information currently available to management.
Slide 3: Sending patient samples across the country is a waste of time
Sending patient samples across the country is a waste of time. 3 iMDxinc.com
Slide 4: High Clinical Demand, Strong Reimbursement, IP Protected
High Clinical Demand Strong Reimbursement IP Protected 4 iMDxinc.com
Slide 5: Transplant Monitoring: $2B Clinical Market in US
Transplant Monitoring: $2B Clinical Market in US Underpenetrated, Inefficient, Ripe for Disruption Opportunity for Increased Adoption Current Opportunity for Disruption Adoption Total Market Send-out Testing In-House Testing $2B ~$500MM $0MM 5 iMDxinc.com
Slide 6: Regulated + Reimbursed + Clinically Useful
Regulated + Reimbursed + Clinically Useful Rapid Adoption 6 iMDxinc.com
Slide 7: Why invest in molecular diagnostics?
Why invest High-value creation Empowers doctors to reduce uncertainty to make better in molecular decisions to save lives. Enables researchers to measure biomarkers to inspire innovation. diagnostics? High-value capture Intellectual property protects our market position, commands high reimbursement
Slide 8: Regulated transplant testing is a $1B+ greenfield global opportunity
Regulated transplant testing is a $1B+ greenfield global opportunity. 8 iMDxinc.com
Slide 9: Partnership: Bio-Rad to help commercialize
Transplant strategic partner: Key terms / Partnership • Bio-Rad (NYSE: BIO) now a top five shareholder with upfront equity investment Bio-Rad to help and two subsequent equity investments commercialize • Coordinated rapid development of IVD platform GraftAssure RUO • At FDA clearance, exclusive nego
Slide 10: Accelerating Momentum
Accelerating Momentum MolDx releases Announced publicly draft LCD on Referenced in August shareholder letter Renamed our company to surveillance testing Medicare boosts First patient enrolled in Insight Molecular Diagnostics Jul 17 reimbursement rate clinical trial May 19 Jun 17 Sep 2 Favorable late
Slide 11: Pioneering Molecular Diagnostics & Disruptive Growth
Experienced leadership Pioneering Molecular Diagnostics & Disruptive Growth Josh Riggs Ekkehard Schütz, Yuh-Min (Johnson) Andrea President & Chief MD, PHD, FADLM Chiang, PHD James Chief Technology Executive Officer Chief Science Officer Chief Financial Officer Officer iMDxinc.com 11
Slide 12: Insight Molecular Diagnostics
T™ X Insight Molecular Diagnostics
Insight Molecular Diagnostics — H.C. Wainwright 27th Annual Global Investment Conference 2025 on 6ix